HANetf’s Medicinal Cannabis Fund (CBDX) Has Been Passported for Distribution in the Netherlands and Finland | CBDX
- The ETF was initially listed in Frankfurt (XETRA) and has
since also been listed on the London Stock Exchange. TER 80bps
This is the first and still the only ETF available in
Europe as a UCITS that tracks medical cannabis
14, February, 2020 - HANetf,
Europe’s first ‘white label’ ETF issuer, has registered its landmark medical
cannabis ETF for sale in the Netherlands and Finland. CBDX – The Medical
Cannabis and Wellness UCITS ETF - was launched in January 2020 on XETRA and
the London Stock Exchange with Purpose Investments as sponsor.
provides investors with the opportunity to gain exposure to a basket of
carefully vetted companies that have high exposure to the medicinal cannabis,
hemp and cannabinoids (CBD) industry. It is the only UCITS ETF which is
providing this level of targeted exposure.
tracks a rules-based Medical Cannabis and Wellness Equity Index from Solactive,
consisting of publicly listed companies conducting legal business activities in
the medical cannabis, hemp and CBD industries. The methodology uses a rigorous
and multi-tiered screening process to identify and exclude companies that are
involved in the adult-use Cannabis market.
constantly monitored to ensure that it remains focused exclusively on stocks
that are dedicated to the medical cannabis market. Companies that have retail
cannabis exposure are screened out.
of CBDX is Purpose Investments of Canada. Purpose is a highly innovative fund
management business with over US$8 billion in assets under management (as of
January 2020). In 2017, Purpose Investments launched a cannabis fund in Canada
(the Purpose Marijuana Opportunities Fund), and have a have a deep
understanding of this exciting, high growth industry sector.
Portfolio Manager at Purpose Investments, commented: “The launch
of CBDX in the UK and Germany comes at a time when the sell-off in cannabis
stocks has created new value and a new entry point for investors interested in
this sector. Medicinal stocks in this sector are again showing value against
long term growth targets. We expect to see further deregulation of medical
cannabis products and additional take up within the healthcare sector in the
near future, which will drive prices.”
Faisal, Director of Product Management at HANetf, added: “While the
North American ETF market is well-served with products that track cannabis
indexes, this is the first and currently only UCITS ETF authorized for distribution
in the European market. With the addition of the Netherlands and Finland as
markets for distribution, more investors will be able to access the
fast-developing medical cannabis story.”
considering CBDX should be aware of the following risks and consult the KIID
and Prospectus on www.hanetf.com for further information.
value of equities and equity-related securities can be affected by daily
stock and currency market movements
capital is fully at risk and investors may not get back the amount
rate fluctuations could have a negative or positive effect on returns
|London Stock Exchange
|London Stock Exchange